A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer-Reference-Cited by-同舟云学术

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer

Published:2015-01-27 Issue:1 Volume:10 Page:e0117002
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Zhou Tie,Zeng Shu-xiong,Ye Ding-wei,Wei Qiang,Zhang Xu,Huang Yi-ran,Ye Zhang-qun,Yang Yong,Zhang Wei,Tian Ye,Zhou Fang-jian,Jie Jin,Chen Shi-ping,Sun Yan,Xie Li-ping,Yao Xing,Na Yan-qun,Sun Ying-hao

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. Cancer statistics, 2014;R Siegel;CA Cancer J Clin,2014

2. Epidemiological trends of prostate cancer: retrospect and prospect;D Ye;China Oncol,2007

3. Characterising the castration-resistant prostate cancer population: a systematic review;M Kirby;Int J Clin Pract,2011

4. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain;DS Ernst;J Clin Oncol,2003

5. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study;PW Kantoff;J Clin Oncol,1999

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular Inflammation, Cancer, and Cardiovascular Diseases;Current Oncology Reports;2023-06-01

2. Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial;BMC Cancer;2022-02-16

3. Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer;Cancers;2022-01-14

4. Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review;Therapeutic Advances in Medical Oncology;2022-01

5. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study;ESMO Open;2021-10